Home / Business and Economy / Maggot Therapy Gains FDA Nod for Tough Wounds
Maggot Therapy Gains FDA Nod for Tough Wounds
17 Jun
Summary
- FDA approved Cuprina's MEDIFLY Maggots for wound debridement.
- The therapy uses medical-grade Lucilia cuprina larvae.
- Cuprina is the sole holder of rights to two maggot species for therapy.
The U.S. Food and Drug Administration has granted 510(k) clearance to Cuprina's MEDIFLY Maggots, a novel prescription product utilizing medical-grade larvae from the Lucilia cuprina species. This approval allows for the debridement of non-healing necrotic skin and soft tissue wounds, encompassing conditions such as pressure ulcers, neuropathic foot ulcers, and complicated traumatic or post-surgical wounds. This marks the first FDA approval for a maggot debridement therapy product derived from the Lucilia cuprina species.
Cuprina Holdings, the company behind this innovation, now possesses exclusive commercial rights to both Lucilia cuprina and Lucilia sericata, the two maggot species employed in maggot debridement therapy (MDT). This dual-species capability offers a strategic advantage, enabling Cuprina to cater to diverse market preferences as it expands its wound-care services internationally, particularly in Asia and the Middle East. The company's initial FDA approval for maggot species dates back to 2004 with the Lucilia sericata species.
